Ceryvyn Therapeutics Ltd
Company Profile
Business description
Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company developing therapies by translating advances in human biology into transformative medicines for patients with serious diseases. The Company seeks to identify biological mechanisms that drive disease and develop targeted therapies capable of addressing unmet medical need. Its current focus is lymphangioleiomyomatosis (LAM) - a rare, chronic and progressive systemic disease that predominantly affects women and involves the lungs, where it leads to progressive loss of lung function. The Company's main development program, CYV-101, is a first-in-class fusion protein designed to selectively bind and neutralise VEGF-C and VEGF-D, key signalling proteins involved in pathological lymphangiogenesis.
Contact
117 Camberwell Road
Suite 1, Level 1
Hawthorn EastVIC3123
AUST: +61 398260399
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
10
Stocks News & Analysis
stocks
Disney earnings: Experiences and streaming again drive excellent results
stocks
ASX utility share downgraded as electricity prices fall
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,445.10 | 33.80 | 0.36% |
| CAC 40 | 8,714.93 | 15.22 | 0.17% |
| DAX 40 | 26,319.45 | 179.32 | 0.69% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,901.09 | 33.20 | 0.31% |
| HKSE | 25,668.03 | 137.75 | 0.54% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 65,606.71 | 76.55 | -0.12% |
| NZX 50 Index | 13,824.13 | 133.93 | -0.96% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,263.60 | 34.80 | 0.38% |
| SSE Composite Index | 3,940.04 | 39.68 | 1.02% |